FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/CagriSema Study Launches to Evaluate Heart Health Benefits in Cardiovascular Disease Patients
返回研究图书馆

CagriSema Study Launches to Evaluate Heart Health Benefits in Cardiovascular Disease Patients

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

CagriSema Study Launches to Evaluate Heart Health Benefits in Cardiovascular Disease Patients

A new clinical trial has started to explore how a combination therapy, CagriSema, affects cardiovascular health in patients with heart disease. The study, called REDEFINE 3 (NCT05669755), is being conducted by Novo Nordisk A/S and aims to understand the potential benefits of this innovative treatment.

Background

Cardiovascular diseases are among the leading causes of death worldwide, making research into new treatments a critical area of focus. CagriSema combines two peptides—cagrilintide and semaglutide—that have shown promise in managing weight and improving metabolic health. The compound's potential to reduce cardiovascular events such as heart attacks and strokes is now being investigated through the REDEFINE 3 trial.

The study follows previous research that has highlighted the importance of addressing both metabolic and cardiovascular issues simultaneously, given their interconnected nature. With obesity and diabetes increasing the risk of heart disease, treatments like CagriSema offer a promising approach to tackle these conditions holistically.

Key Details

REDEFINE 3 is currently in Phase 3 and is actively recruiting participants for its study. The trial will compare the effects of CagriSema with those of a placebo among individuals diagnosed with cardiovascular disease. Participants are randomly assigned to receive either the experimental treatment or the placebo, ensuring an unbiased evaluation of CagriSema's efficacy.

The study involves weekly injections of CagriSema for participants who receive it, allowing researchers to monitor its long-term impact on heart health and overall well-being. By assessing cardiovascular events as primary endpoints, the trial aims to provide clear evidence regarding CagriSema’s effectiveness in reducing risks associated with heart disease.

Key Takeaways

  • Investigating a Novel Combination Therapy: The REDEFINE 3 study focuses on evaluating CagriSema, which combines cagrilintide and semaglutide, to determine its benefits for cardiovascular health.
  • Randomized Controlled Trial Design: Participants are randomly assigned to receive either the investigational treatment or a placebo, ensuring that results can be attributed directly to the therapy's effects.
  • Focus on Cardiovascular Events: The primary goal is to measure reductions in heart attacks and strokes among those treated with CagriSema compared to those receiving a placebo.
  • Implications for Future Treatment Options: Successful outcomes could lead to new treatment options for managing cardiovascular disease alongside metabolic conditions like obesity and diabetes.

What This Means

For the peptide community, the REDEFINE 3 trial represents another step forward in understanding how peptides can be used to improve heart health. As research continues to show the potential of peptides in various therapeutic areas, studies like this one are crucial in establishing their clinical value.

With an increasing number of regulatory bodies around the world recognizing the importance of peptide-based treatments, findings from REDEFINE 3 could pave the way for broader acceptance and utilization of these therapies. For clinicians and researchers alike, the results of this trial will provide valuable insights into managing cardiovascular disease more effectively, potentially leading to better patient outcomes.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。